SCHEMBL6989099

SCHEMBL6989099

COCCOCCN1CC2CC(C1)CN(CC(O)COc1ccc(C#N)cc1)C2

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.51
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
GLA P06280 1/20 0.43
HTT P42858 1/20 0.42
RAD52 P43351 1/20 0.42
AGER Q15109 1/20 0.42
HRH2 P25021 1/20 0.41
HRH1 P35367 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 2/20 0.41
MAPK1 P28482 1/20 0.41
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093113 0.93 KCNH2 (0.53) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL6093106 0.93 KCNH2 (0.53) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL2964519 0.89 KCNH2 (0.64) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL7035866 0.86 HRH3 (0.49) HRH2HRH1HRH3SMN1; SMN2
SCHEMBL7032087 0.86 KDM4E (0.60) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL7032100 0.86 KDM4E (0.60) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL6993777 0.86 KDM4E (0.60) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL6993770 0.86 KDM4E (0.60) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL5966008 0.85 KCNH2 (0.46) KCNH2KDM4EALDH1A1MEN1KMT2A
SCHEMBL7033470 0.85 KCNH2 (0.55) KCNH2KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E KCNH2 7/4885KDM4E 4058/4885ALDH1A1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.